Table 1 Clinical, biological and haemodynamic characteristics of the total population (n = 149) before CM injection

Age (years)

64 [56–72]

Sex (male, %)

92 (62)

ICU admission diagnosis (medical/surgical)

113/36

APACHE II score

20 [14–25]

Weight (kg)

78.0 [70.0–90.0]

Diabetes mellitus (%)

41 (27.5)

Cardiovascular risk factors (%)

104 (69.8)

Need for renal replacement (%)

6 (4)

Length of ICU stay (days)

12 [7–21]

ICU mortality (%)

35 (23.5)

Haematocrit (%)

31.4 [27.1–38.3]

Urea (mg/dL)

44.4 [32.0–58.1]

Creatinine (mg/dL)

0.91 [0.64–1.13]

MDRD (mL/min/1.73 m²)

77.7 [54.5–113.4]

Patients with creatinine ≥1.5 mg/dL (%)

15 (10)

pH

7.40 [7.33–7.46]

BE (meq/L)

0.00 [−3.00–4.25]

HCO3 (mg/dL)

24.8 [21.6–29.2]

Na (mEq/L)

140 ± 5

Lactate (mmol/L)

0.5 [0.4–0.8]

Nephropathy prevention (%)

29 (19.5)

Mean blood pressure before CM injection (mmHg)

81 [71–93]

CVP (mmHg)

9 [6–12]

Maximal vasopressor dose (mcg/kg/min)

0.00 [0.00–0.08]

Fluid intake, day 0 (mL)

2830 [2114–3621]

Doses of CM (ml/kg)

1.6 [1.31–2.29]

Nephrotoxic drugs (%)

66 (44.3)

Diuretics (%)

24 (16.1)